Study of nasopharyngeal bacterial flora. Second report. Variations in nasopharyngeal bacterial flora in children aged 6 years or younger when administered antimicrobial agents. Part 2
Masatoshi Konno(National Hospital Organization), Kimiko Ubukata(Tokyo Medical University), Kunihiko Kobayashi(Saitama International Medical Center), Harukí Mikawa(University of Fukui), Matsuhisa Inoue(Kitasato University), Kohei Hara(Nishikawa Hospital), Fumio Matsumoto(Jikei University School of Medicine), Toshimitsu Kobayashi(Tohoku University), Shigeru Kohno(Nagasaki University), Mituru Furukawa(Kanazawa University), Shunkichi Baba(Nagoya City University), Akihiro Morikawa(Gunma University), Hiroshi Moriyama(Jikei University School of Medicine), Toshiharu Matsushima(Kawasaki Medical School), Shoichi Koizumi(Kanazawa University), Yasuyuki Yoshizawa(Tokyo Medical and Dental University), Keisuke Sunakawa(Kitasato University), Kimitaka Kaga(The University of Tokyo), Nobuhiko Furuya(Gunma University), Yoshitaka Okamoto(Chiba University), Noboru Yamanaka(Wakayama Medical University), Tadao Nishimura
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|Annals of Oncology|2012|555
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
|Journal of Clinical Oncology|2019|490